Document:

<PAGE>

                                                                    EXHIBIT 10.2
                                                                    ------------

Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as **. A complete version of this exhibit has been
filed separately with the Securities and Exchange Commission.

                         OPTION AND LICENSE AGREEMENT
                         ----------------------------

THIS AGREEMENT (the "Agreement") is made and is effective the 10th day of June,
1998 (the "Effective Date") by and between:

           Adolor Corporation, a Delaware corporation having its principal place
           of business at 371 Phoenixville Pike, Malvern, Pennsylvania 19355
           ("ADOLOR")

     and

           Roberts Laboratories Inc., a New Jersey corporation, having its
           principal place of business at 4 Industrial Way West, Eatontown, New
           Jersey 07724 ("ROBERTS").

                                   RECITALS
                                   --------

1.   ADOLOR is engaged in the development and marketing of therapeutic products
     utilizing opiate receptor-mediated pathways.

2.   ROBERTS has acquired from Eli Lilly and Company ("Lilly"), in an agreement
     dated November 5, 1996 (the "Lilly License"), an exclusive, world-wide
     license to make, have made, use or sell (+)-[2(S)-[4(R)-(3-hydroxyphenyl)-
     3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-acetic
     acid and all pharmaceutically acceptable salts and solvates thereof (the
     "Compound"), with the right to sublicense, which Lilly License and its
     Appendices A and B are appended hereto as Exhibit A.

3.   An Investigational new Drug Application ("IND"), made to the United States
     Food and Drug Administration ("FDA"), was initiated for the Compound, but
     currently there is no activity pursuant to this Application.

4.   As ADOLOR believes the Compound may provide the basis for a therapeutic
     product utilizing opiate receptor-mediated pathways, ADOLOR desires to
     obtain and ROBERTS desires to provide an exclusive, world-wide license
     including (a) a "Phase A" during which ADOLOR will seek to establish the
     therapeutic index of the Compound, and (b), provided the therapeutic index
     is satisfactory to ADOLOR at its sole discretion, a "Phase B" during which
     ADOLOR will pursue development and commercialization of the Compound.

5.   Assuming ADOLOR proceeds to Phase B, ADOLOR further desires to seek to
     convert the license to an assignment of the Lilly License to ADOLOR subject
     to the same duties as between ADOLOR and ROBERTS as are set forth below,
     and ROBERTS desires to deliver such assignment to ADOLOR and to exert best
     efforts to obtain for ADOLOR the required permission from Lilly, though in
     the absence of such an assignment the license provided herein shall be
     maintained.

NOW THEREFORE, in consideration of the mutual covenants and obligations
hereinafter set forth the parties agree to be legally bound as follows:
<PAGE>

ARTICLE I      - DEFINITIONS
----------------------------

     Section 1.1.   "Affiliate," "Compound," "End User," "Lilly Intellectual
     ------------
Property Rights," "Net Sales" and "Product" shall have the meanings,
respectively, set forth in the Lilly License.

     Section 1.2.   "First Commercial Sale" shall mean the first time sales are
     ------------
made of Product by ADOLOR to an unrelated third party on a country by country
basis.

     Section 1.3.   "Lilly Know-How" shall have the meaning set forth for "Know-
     ------------
How" in the Lilly License.

     Section 1.4.   "NDA" shall mean an application filed with the FDA for the
     ------------
approval of the manufacturing, marketing or importation of a therapeutic product
for use in humans. The references below to "similar filing" shall encompass, for
example, Product License Applications ("PLAs") and Pre-Marketing Applications
("PMAs").

     Section 1.5.   "Technical Information" shall mean Technology which is
     ------------
owned, discovered or developed by or licensed to ROBERTS which is embodied or
employed in the composition, manufacture or use of the Compound or Product, or
components, reagents, parts or elements thereof. "ADOLOR Technical Information"
shall mean Technology which is owned, discovered or developed by ADOLOR which is
embodied or employed in the composition, manufacture or use of the Compound or
Product, or components, reagents, parts or elements thereof.

     Section 1.6.   "Technology" shall mean know-how, protocols, processes,
     ------------
instruments, machines, materials, compositions, tests procedures, manufacturing
procedures, techniques, formulations, methodologies and data, inventions,
observations and information, related to the Compound or the Product.

ARTICLE II     LICENSE
----------------------

Pursuant to the Lilly Intellectual Property Rights or any ROBERTS Technical
Information, ROBERTS grants ADOLOR an exclusive, world-wide license to make,
have made, use, sell or import Product pursuant to the Lilly Intellectual
Property Rights or any other ROBERTS Technical Information. The term of the
license shall be either the term of Phase A or, if ADOLOR elects to proceed with
Phase B, the sum of the terms of Phase A and Phase B.

The rights acquired hereunder shall include all rights licensed to ROBERTS
pursuant to the Lilly License.
<PAGE>

ARTICLE III    - PHASE A
------------------------

     Section 3.1.   - Phase A Consideration
     --------------------------------------

     In consideration for Phase A, ADOLOR shall deliver to ROBERTS a non-
refundable payment of $300,000 on the Effective Date.

     Section 3.2.   - Phase A Term
     -----------------------------

The term of Phase A shall be from the Effective date until the earlier of (a)
the date on which ADOLOR delivers to ROBERTS notice of ADOLOR's completing
studies sufficient to establish the therapeutic index of the Compound and of
whether ADOLOR intends to initiate Phase B and (b) July 31, 1999. The parties
acknowledge that there are areas of risk to ADOLOR's ability to meet this
timetable including:

     .     the risk that the pharmaceutical composition of the Compound or
           Product provided by ROBERTS be insufficient in quality or quantity to
           conduct the studies necessary to establish the therapeutic index; and

     .     the risk that the FDA will suspend or place on hold any activity
           pursuant to the IND for the Compound.

The parties further acknowledge that the above exemplified risks, should they
become realities, would provide cause for the July 31, 1999 term expiration date
to be extended. Should an event outside of ADOLOR's control give rise to a
reasonable basis to extend the July 31, 1999 term expiration date, meaning that
it is reasonable to expect that ADOLOR acting with commercially reasonable
diligence shall not have completed studies to establish the therapeutic index of
the Compound by July 31, 1999, an extension of time will be provided to enable
ADOLOR to complete the studies and the parties shall negotiate in good faith and
arrive at a reasonable period of extension.

     Section 3.3.   - ADOLOR's Phase A Duties
     ----------------------------------------

     In addition to any other duties imposed by this Agreement, during the term
of Phase A, ADOLOR shall use commercially reasonable efforts to conduct studies,
including Phase I clinical studies, to establish the therapeutic index of the
Compound. All costs associated therewith shall be borne by ADOLOR. While the
Phase A is in effect, ADOLOR agrees to undertake the obligations incumbent on
ROBERTS under the Lilly License, with the exception of the milestone payments
set forth in Section 3.01 of the Lilly License and the costs associated with
prosecuting or maintaining patents under the Lilly Intellectual Property Rights,
which shall continue to be borne by ROBERTS.
<PAGE>

     Section 3.4.   - ROBERTS' Phase A Duties
     ----------------------------------------

     In addition to any other duties imposed by this Agreement, ROBERTS shall:

     (a)   provide ADOLOR its stocks of the Compound, in the amount ROBERTS
           possesses in whatever condition that such Compound may be as of the
           Effective Date; and

     (b)   during the term of Phase A, refrain from discussing, negotiating or
           agreeing to, with a third party, a license or assignment of rights in
           the Compound, or its use, manufacture, sale or import.

ARTICLE IV     - PHASE B
------------------------

     Section 4.1.   - Term and Contingency
     -------------------------------------

     The term of Phase B begins on the last day of Phase A through to the end of
the term defined in Section 8.01 of the Lilly License. Entrance into Phase B is
contingent on ADOLOR delivering to ROBERTS during the term of Phase A notice of
ADOLOR's intent to proceed with Phase B.

     Section 4.2.   - Phase B Consideration
     --------------------------------------

Subject to the foregoing, in consideration for Phase B, ADOLOR shall pay
ROBERTS:

     .     $300,000 payable within five (5) business days of the expiration of
           Phase A;
     .     $** payable within five (5) business days of the filing of a first
           application for a NDA or similar filing in the United States, Canada,
           Japan or the European Community that seeks permission to market a
           Product;
     .     $** payable within five (5) business days of receiving notice of
           acceptance of a first NDA or similar filing in the United States,
           Canada, Japan or the European Community that seeks permission to
           market a Product; and
     .     a royalty equal to **% of Net Sales.

ADOLOR shall pay Lilly, on behalf of ROBERTS, $** upon acceptance of a first NDA
or similar filing in the United States, Canada, Japan or the European Community
that seeks permission to market a Product, in accordance with Section 3.01(v)
the Lilly License. ADOLOR agrees to pay Lilly, on behalf of ROBERTS, a royalty
equal to ** % of Net Sales in accordance with the Lilly License. For any payment
made on behalf of ROBERTS, ADOLOR shall deliver proof of such payment to
ROBERTS.

**=Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to
   the omitted portions.

<PAGE>

     Section 4.3.   - ADOLOR's Phase B Duties
     ----------------------------------------

While Phase B is in effect, ADOLOR agrees to undertake the obligations incumbent
on ROBERTS under the Lilly License and accruing during Phase B, with the
exception of the execution milestone payment set forth in Section 3.01(a)(i) of
the Lilly License. Except for costs associated with Robert's duties under this
Agreement, all costs associated with developing and commercializing the Compound
or Product shall be borne by ADOLOR.

ARTICLE V      - SUBLICENSES OF THIS AGREEMENT
----------------------------------------------

     (a)   ADOLOR shall have the right to grant sublicenses hereunder consistent
           with the terms of the Lilly License, provided, however, that should
                                                -----------------
           ADOLOR grant a sublicense hereunder within seventy-five (75) days of
           the Effective Date, ROBERTS shall receive 25% of any payments made to
           ADOLOR in consideration of such sublicense.

     (b)   Should ADOLOR decide to actively seek to sublicense marketing rights
           in the Compound or seriously consider a good faith offer by a third
           party to sublicense such marketing rights, ADOLOR shall notify
           ROBERTS of its intention to seriously seek to sublicense the
           marketing rights and shall provide ROBERTS with an opportunity to
           negotiate in good faith for a sublicense to the marketing rights.
           However, nothing herein shall imply that ROBERTS has a right of
           priority or preference in such negotiations, or imply any restraints
           whatsoever on ADOLOR's business judgment as to partners in marketing
           the Compound.

ARTICLE VI     - TECHNOLOGY TRANSFER
------------------------------------

     Section 6.1.   - From ROBERTS to ADOLOR
     ---------------------------------------

     Following execution and payment under Section 3.1 ROBERTS shall deliver to
ADOLOR copies of the Lilly Know-how, ROBERTS Technical Information, and its
inventory of Compound and intermediates for the production of Compound.

     Section 6.2.   - From ADOLOR to ROBERTS
     ---------------------------------------

     (a)   Should ADOLOR establish the therapeutic index of the Compound but
           nonetheless decline to initiate Phase B, ADOLOR shall deliver to
           ROBERTS copies of ADOLOR data on the therapeutic index of the
           Compound and any other ADOLOR data on the therapeutic efficacy of the
           Compound as well as any dosage forms containing the Compound.
<PAGE>

     (b)   Should ADOLOR fail to establish the therapeutic index and should
           ADOLOR not dispute that the term of Phase A, taking into
           consideration any extensions thereto under Section 3.2, has expired,
           then ADOLOR shall deliver to ROBERTS copies of ADOLOR data on the
           therapeutic index of the Compound and any other ADOLOR data on the
           therapeutic efficacy of the Compound as well as any dosage forms
           containing the Compound.

     (c)   All such materials delivered to ROBERTS pursuant to this Section 6.2
           shall thus become the sole and exclusive property of ROBERTS.

ARTICLE VII    - REPORTS, RECORDS, PAYMENTS
-------------------------------------------

     Section 7.1.   - Quarterly Reports
     ----------------------------------

     (a)   ADOLOR shall give ROBERTS prompt written notice of-the first
           acceptance of a NDA or similar filing in the United States, Canada,
           Japan or the European Community that seeks permission to market a
           Product.

     (b)   Within forty five (45) days after the end of each calendar quarter
           following the First Commercial Sale in any country, whether or not a
           royalty payment is due for that period, ADOLOR shall provide ROBERTS
           with a written statement with respect to such period, specifying the
           gross sales, the calculation of Net Sales and Net Sales of Product
           during the period, and the amount of royalty due, if any, together
           with the payment of royalties due.

     Section 7.2.   - Records
     ------------------------

     (a)   ADOLOR shall keep complete and accurate records pertaining to the
           manufacture, use and sale of Product appropriate to determine
           royalties payable under Section 4.2 of this Agreement.

     (b)   At the request and expense of ROBERTS, an independent certified
           public accountant, selected by ROBERTS and reasonably approved by
           ADOLOR, shall have access limited to once per calendar year, at
           ADOLOR's principal place of business during ordinary business hours,
           to such records maintained by ADOLOR as may be necessary to:

           (i)   determine, with respect to any of the two (2) preceding years
     the correctness of any report or payment made under this Agreement, or

           (ii)  obtain information with respect to any of the two (2) preceding
     years as to the royalty payable in the case of ADOLOR's failure to report
     or pay such royalty pursuant to this Agreement.
<PAGE>

     (c)   If deemed necessary or desirable in the sole opinion of the
           accountant, the accountant shall at ROBERTS' expense be permitted to
           consult with and obtain the assistance of consultants selected by the
           accountant and reasonably acceptable to ADOLOR. Neither the
           accountant nor the selected consultants shall disclose to ROBERTS or
           any third pasties any information relating to the business of ADOLOR
           other than information relating solely to the accuracy of the reports
           and payments under this Agreement.

     Section 7.3.   - Payment of Royalty
     -----------------------------------

     (a)   ADOLOR shall pay the royalty due under Section 4.2 for sales of
           Product in each calendar quarter within forty five (45) days after
           the end of such calendar quarter.

     (b)   All royalty due hereunder shall be paid in same day United States
           funds.

     (c)   Any sum required under the laws of any governmental authority to be
           withheld by ADOLOR from payment of royalties for the account of
           ROBERTS under Section 4.2 shall be promptly paid by ADOLOR for and on
           behalf of ROBERTS to the appropriate tax or other governmental
           authorities and ADOLOR shall furnish ROBERTS with copies of official
           tax receipts or other appropriate evidence issued by the appropriate
           tax or other governmental authorities.

     (d)   Should an audit under Section 7.2(b) identify a delinquency in
           royalties due. ADOLOR shall pay, in addition to such delinquent
           amount, liquidated damages of 1 1/2% of the delinquency per month of
           the delinquency. Should such delinquency in any year exceed five
           percent (5%), ADOLOR shall pay for the audit fees and expenses
           incurred by ROBERTS.

ARTICLE VIII   - CONFIDENTIALITY
--------------------------------

     Section 8.1.   - Nondisclosure and Nonuse
     -----------------------------------------

     (a)   ROBERTS and ADOLOR shall each retain in confidence information
           obtained from the other under this Agreement and shall not disclose
           such information to any third party except:

           (i)   consultants and Affiliates who are obligated to maintain it in
     confidence pursuant to written agreements which incorporate the terms of
     this Article VIII.

           (ii)  as necessary to obtain approval from a governmental agency in
     order to market the Product; or

           (iii) as otherwise may be required by law, regulation or judicial
     order, and shall not use such information for any purposes other than those
     contemplated by this Agreement. Each party shall take all reasonable
     precautions to safeguard the confidentially of the information.
<PAGE>

     Section 8.2.   - Exceptions
     ---------------------------

The obligations of nondisclosure and nonuse of this Article VIII shall not apply
to information which:

     (a)   is known to the receiving party, as evidenced by written records
           maintained by the receiving party, or to the public, or is in the
           public domain, prior to its disclosure under this Agreement;

     (b)   is hereafter lawfully disclosed to the receiving party by a third
           party not- under an obligation of confidence to the other party;

     (c)   subsequently enters the public domain or becomes known to the public
           by some means other than a breach of this Agreement;

     (d)   is required by law to be disclosed; or

     (e)   becomes the property of the property of the disclosing party pursuant
           to this Agreement.

     Section 8.3.   - Purpose of Article
     -----------------------------------

Each party acknowledges that the restrictions contained in this Article VIII are
necessary and reasonable to protect the legitimate interests of the parties and
a violation of this Article by a party may result in irreparable harm to the
other party.

     Section 8.4.   - Term
     ---------------------

The provisions of this Article VIII shall survive the expiration or termination
of this Agreement and continue for five (5) years thereafter.

     Section 8.5.   - Merger
     -----------------------

Upon execution, all confidential information relating to the Compound disclosed
under any previous confidentially agreements between ROBERTS and ADOLOR shall be
governed by this Agreement instead of such prior agreement.

ARTICLE IX     - INVENTIONS AND PATENTS
---------------------------------------

     (a)   While licensed under Phase B, ADOLOR shall make the payments for
           prosecuting and maintaining patent applications set forth in Section
           4.03 of the Lilly License.
<PAGE>

     (b)   While ADOLOR is licensed under Phase B, should Lilly elect, in any
           country, to not prosecute or maintain an application or not to
           maintain or defend an issued patent, ADOLOR shall be given timely
           notice and shall have the right to direct that such prosecution,
           maintenance or defense be conducted at ADOLOR's expense. If (1)
           ADOLOR declines to undertake such expense, (2) the application or
           patent at issue is the only Lilly patent or Application covering the
           Compound, its synthesis, use or formulation in the given country, and
           (3) such prosecution, maintenance or defense is conducted at ROBERTS'
           expense, the license granted by this Agreement shall no longer apply
           with respect to such county.

     (c)   While ADOLOR is licensed under Phase B, Lilly may, pursuant to
           Section 4.03 of the Lilly License, send notice to ROBERTS of a cost
           associated with prosecuting, maintaining or defending an application
           or patent in a given country, a copy of which notice shall be timely
           forwarded to ADOLOR. If ADOLOR elects not to pay such costs, ROBERTS
           may on its own account, without compensation from ADOLOR, undertake
           the costs payable to Lilly. If (1) ADOLOR elects not to pay such
           costs, (2) the application or patent at issue is the only Lilly
           patent or application covering the Compound, its synthesis, use or
           formulation in the country, and (3) the costs payable to Lilly for
           such prosecution, maintenance or defense are undertaken by ROBERTS,
           the license granted by this Agreement shall no longer apply with
           respect to such county.

     (d)   An official of ADOLOR designated by ADOLOR shall receive copies from
           ROBERTS of all significant correspondence to and from the U.S. Patent
           and Trademark Office or other, foreign patent administrative body
           relating to Licensed Patents.

     (e)   ROBERTS shall consult with ADOLOR on any matters arising under
           Section 4.06 of the Lilly License (regarding reexamination, reissue
           other proceedings relating to granted patents), and ROBERTS shall
           provide no Consent under that Section 4.06 without the prior consent
           of ADOLOR.

     Section 9.2.   - Third-Party Infringement
     -----------------------------------------

     (a)   If either ADOLOR or ROBERTS learns of an infringement or threatened
           infringement of Lilly Intellectual Property Rights or ADOLOR or
           ROBERTS Technical Information wherein the infringement or threatened
           infringement involves a third party's manufacture, or sale of
           Compound or Product, the party who so learns shall notify the other
           party within a reasonable time.
<PAGE>

     (b)   While ADOLOR is licensed under Phase B, ADOLOR shall have the rights
           allocated to ROBERTS in Section 4.05 of the Lilly License to
           participate in actions to terminate an infringement of Lilly
           Intellectual Property Rights. ROBERTS will execute (and cause its
           Affiliates to execute) all documents necessary to effect this
           provision. While ADOLOR is licensed under Phase B, ADOLOR shall have
           the same rights to participate in actions to terminate an
           infringement of ROBERTS Technical Information as ROBERTS has with
           respect to Lilly Intellectual Property Rights under the Lilly
           License.

     (c)   With respect to an action involving Lilly, the parties shall endeavor
           to have recoveries allocated in proportion to reasonable costs
           incurred by the parties. With respect to actions not involving Lilly,
           recoveries shall be so allocated.

ARTICLE X      - EXPIRATION AND TERMINATION
-------------------------------------------

     Section 10.1.  - Expiration
     ---------------------------

Unless terminated earlier under other provisions of this Agreement will expire
at the end of the term set forth Section 8.01 of the Lilly License.

     Section 10.2.  - Surviving Rights
     ---------------------------------

The provisions of 10.3 (Termination) and 12.5 (Governing Law) and Article VIII
(CONFIDENTIALITY) of this Agreement shall survive the expiration or termination
of this Agreement.

     Section 10.3.  - Termination
     ----------------------------

     (a)   ADOLOR may terminate this agreement with respect to Phase A by
           delivering notice of such termination to ROBERTS at least thirty (30)
           days prior to the effective date of such termination.

     (b)   Either party may terminate this Agreement upon (60) days prior
           written notice in the event of the other party's breach of any other
           material provision of this Agreement, if such default or breath is
           not remedied within sixty (60) days from the date of such notice.

     (c)   Any failure to terminate shall not be construed as a waiver by the
           aggrieved party of its right to terminate for future defaults or
           breaches.

     (d)   Upon termination of this Agreement, each party shall upon the request
           of the other party return all books, records, documents and data
           which it shall have received from the other party pursuant to this
           Agreement.
<PAGE>

     (e)   Termination of this Agreement by either party shall not prejudice the
           right of ROBERTS to recover any royalty or other payments due at the
           time of termination or which become due after termination based upon
           rights vested prior to termination and shall not prejudice any cause
           of action or claim of ROBERTS or ADOLOR accruing under this
           Agreement.

     (f)   ADOLOR shall not make, have made, use or sell the Compound or Product
           following termination of this Agreement, except that if termination
           occurs during Phase B ADOLOR may sell such stocks of the Compound or
           Product as it shall have on hand at the time of termination. This
           provision shall not exempt ADOLOR from the duty to pay royalty at the
           rates and times provided under this Agreement.

     (g)   ROBERTS shall not terminate this Agreement during Phase A and any
           term extensions pursuant to Section 3.2, provided that ADOLOR is
           proceeding in good faith to seek to establish the therapeutic index
           of the Compound.

ARTICLE XI     - REPRESENTATIONS, WARRANTIES, COVENANTS
-------------------------------------------------------

     (a)   ROBERTS represents and warrants that it is not in breach of the Lilly
           License and that it has the right to grant the licenses provided this
           Agreement

     (b)   ROBERTS represents and warrants that it shall not take any action or
           refrain from any action so as to give Lilly cause to terminate the
           Lilly License.

     (c)   ROBERTS represents and warrants that it has undertaken no action, and
           that it knows of no action or other change of circumstances, that has
           diminished the value of the Lilly Intellectual Property Rights
           relative to the Lilly Intellectual Property Rights as they existed,
           or as ROBERTS understood them, on the fifth (5th) day of November,
           1996, when the Lilly License was executed.

     (d)   ROBERTS shall use best efforts to obtain from Lilly permission to
           assign the Lilly License to ADOLOR, and, on obtaining such permission
           and receiving notice from ADOLOR of ADOLOR's intent to initiate Phase
           B, shall assign the Lilly License to ADOLOR subject to the same
           duties as between ROBERTS and ADOLOR as set forth in this Agreement.
           Accordingly, this Agreement shall be, with respect to Phase B,
           converted to an agreement to assign.

     (e)   ROBERTS shall make available to ADOLOR personnel reasonably
           appropriate to help ADOLOR understand and implement the Lilly Know-
           how and the ROBERTS Technical Information. Such personnel shall
           include Phil Lange and shall be made available on ADOLOR's request
           for a period not to exceed five (5) working days.
<PAGE>

ARTICLE XII    - MISCELLANEOUS PROVISIONS
-----------------------------------------

     Section 12.1.  - Entire Understanding
     -------------------------------------

This Agreement sets forth the entire understanding between ROBERTS and ADOLOR
pertaining to its subject mailer and supersedes and replaces all prior oral or
written agreements between ROBERTS and ADOLOR pertaining to such subject matter.

     Section 12.2.  - Amendment
     --------------------------

This Agreement may not be amended, supplemented or otherwise modified except by
an instrument in writing signed by both parties.

     Section 12.3.  - Assignment
     ---------------------------

Neither party may assign this Agreement without the prior written approval of
the other party except in connection with the sale or merger of the entire
business or in connection with an assignment to an Affiliate. Such approval
shall not unreasonably be withheld. Notwithstanding such approval, the assigning
party shall be responsible to the party jointly or severally, with the assignee
for any obligations under this Agreement.

     Section 12.4.  - Waiver
     -----------------------

No provision of this Agreement shall be waived by any act, omission or knowledge
of a party or its agents or employees, except by an instrument in writing
expressly waving such provision and signed by the waiving party.

     Section 12.5.  - Governing Law
     ------------------------------

The Agreement shall be governed by and interpreted in accordance with the laws
of the Commonwealth of Pennsylvania, exclusive of its conflict of laws
provisions, and the parties consent to the jurisdiction and to venue at, a court
within the District of the United States Federal Courts in which the defendant
shall be found.

     Section 12.6.  - Restriction of Distribution of this Agreement
     --------------------------------------------------------------

This Agreement shall not be distributed to persons other than those personnel of
ROBERTS and ADOLOR who shall have a need to know its contents and to those whose
knowledge of its contents will facilitate performance of the obligations of the
parties under this Agreement, except as may be required by law, regulation or
judicial order.

     Section 12.7.  - Publicity
     --------------------------

Notwithstanding the provisions of Section 12.6, either party may publicly
announce the existence of this Agreement and the nonfinancial terms contained
herein, provided such announcement is consented to by Lilly. The parties shall
consult with each other prior to any press release or other public disclosure.
<PAGE>

     Section 12.8.  - Consents Not Unreasonably Withheld or Delayed
     --------------------------------------------------------------

Whenever a provision is made in this Agreement for either party to secure the
consent, approval or acceptance of the other, such consent, approval or
acceptance shall not unreasonably be withheld or delayed.

     Section 12.9.  - Construction
     -----------------------------

The captions appearing in this Agreement are for reference purposes only and
shall not be considered for the purpose of interpreting or construing this
Agreement. The plural shall be substituted for singular numbers in any place in
which the context may require such substitution.

     Section 12.10. - Invalidity of Particular Provisions
     ----------------------------------------------------

If any provision of this Agreement is invalid or unenforceable by reason of any
rule of law, administrative order or judicial decision, all other provisions of
this Agreement shall remain in full force and effect.

     Section 12.11. - Notices
     ------------------------

Any notice or report required or permitted hereunder shall be given in writing
by personal delivery or by registered or certified mail, return receipt
requested, postage prepaid, and, if sent by mail, shall be effective upon
delivery to the following addresses:

          ROBERTS LABORATORIES INC.
          4 Industrial Way West
          Eatontown, New Jersey 07724
          ATTN: A.A. Rascio, Vice President

          ADOLOR CORPORATION
          371 Phoenixville Pike
          Malvern, Pennsylvania 19355
          ATTN: President

or such other address as a party may designate by prior written notice to the
other party.

     Section 12.12. - Payment Method
     -------------------------------

All payments by ADOLOR to ROBERTS under this Agreement shall be by wire transfer
of same day funds to ROBERTS' bank account. ROBERTS shall supply ADOLOR with the
bank, routing and account information needed for such a wire transfer.

     Section 12.13. - Late Payments
     ------------------------------

All payments due ROBERTS under this Agreement which are received later than the
due date, shall be subject to an additional payment of one and one-half percent
(1.5%) per month or portion thereof as liquidated damages for payments received
later than the due date.
<PAGE>

     Section 12.14. - Currency
     -------------------------

All references to currency and payments shall be in U.S. dollars.

     Section 12.15. - Force Majeure
     ------------------------------

Each party hereto shall be relieved of its obligations hereunder to the extent
that fulfillment of such obligations shall be prevented by acts of war, labor
difficulties, riot, fire, flood, hurricane, wind storm, acts of defaults of
common carriers, governmental laws, act or regulations (including withdrawal or
suspension of governmental approval of sale of Product), shortages of materials
or any other occurrence beyond the control of the party affected thereby.

(Any Remainder of this page beyond this line is intentionally left blank.)
<PAGE>

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in
duplicate by their duly authorized representatives.

                                        ADOLOR CORPORATION

                                        By:  /s/ John J. Farrar
                                             -----------------------------------

                                        Title:  President and Chief Executive
                                                --------------------------------
                                                Officer
                                                -------

                                        Date:   June 8, 1998
                                                --------------------------------

                                        ROBERTS LABORATORIES INC.

                                        By:  /s/ Anthony A. Rascio
                                             -----------------------------------

                                        Title:  VP
                                                --------------------------------

                                        Date:   6/10/98
                                                --------------------------------

In order to induce Adolor Corporation to execute this Agreement, Robert
Pharmaceutical Corporation, the parent company of Robert Laboratories Inc.,
hereby unconditionally guarantees the due payment and performance of all
obligations of Roberts Laboratories Inc. contained in this Agreement.

                                        ROBERTS PHARMACEUTICAL CORPORATION

                                        By:  /s/ Anthony A. Rascio
                                             -----------------------------------

                                        Title:  VP
                                                --------------------------------

                                        Date:   6/10/98
                                                --------------------------------<PAGE>

                                                                    EXHIBIT 10.3

Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as **. A complete version of this exhibit has been
filed separately with the Securities and Exchange Commission.

                               LICENSE AGREEMENT
                               -----------------

          THIS AGREEMENT is made and is effective this 5/th/ day of November
1997 (the "Effective Date") by and between:

          ADOLOR CORPORATION, a Delaware corporation, having its principal place
of business at 371 Phoenixville Pike, Malvern, Pennsylvania ("ADOLOR") and

          KWANG DONG PHARMACEUTICAL COMPANY, LTD., a Korean corporation, having
its principal office at 212-13, Kuro-dong, Kuro-ku, Seoul, South Korea ("K WANG
DONG").

                                   RECITALS
                                   --------

          1.   KWANG DONG is engaged, inter alia, in the development,
manufacture and sale of pharmaceuticals in the Republic of South Korea.

          2.   ADOLOR is engaged, inter alia, in the research, development, and
sale of pharmaceuticals directed to pain management.

          3.   ADOLOR has received an exclusive license for certain patents and
patent applications related to ADL 2-1294 from the Regents of the University of
California.

          4.   ADOLOR has certain intellectual property related to ADL 2-1294
and its topical use as an anti-hyperalgesic.

          5.   The parties wish to enter into this Agreement to provide license
of ADOLOR's topical anti-hyperalgesic ADL 2-1294 to KWANG DONG.

          NOW THEREFORE, in consideration of the mutual covenants and
obligations hereinafter set forth the parties agree to be legally bound as
follows:

ARTICLE I           DEFINITIONS
                    -----------

Section 1.1.   "FDA" shall mean the United States Food and Drug Administration
               or such other agency or instrumentality of the United States to
               which the responsibilities and authority of the FDA are given or
               delegated from time to time, and the foreign equivalents thereof.

Section 1.2.   "Field" shall mean topical use on skin in humans for anti-
               hyperalgesia, alone or in combination with other topical
               products. The Field shall not include the use for dental,
               ophthalmic, mucosal, parental, injectable, vaginal, and oral
               administration.
<PAGE>

Section 1.3.   "Formulation" shall mean the topical formulation of ADL 2-1294
               for use in the Field provided by ADOLOR which is the subject of
               FDA submissions.

Section 1.4.   "Know-How" shall mean Technology, patented or not, discovered or
               developed by ADOLOR prior to or during the term of this
               Agreement, which is pertinent to the manufacture, sale, or use of
               the Licensed Product and anti-hyperalgesics.

Section 1.5.   "Licensed Patent" shall mean International Patent Application
               PCT/US96/14727, filed September 12, 1996, and corresponding
               patent applications and patents in the Territory.

Section 1.6.   "Licensed Product" shall mean a composition containing ADL 2-1294
               adapted for use in the Field. Licensed Product shall be deemed to
               embody Know-How.

Section 1.7.   "Net Sales" shall mean total gross sales of Licensed Products
               sold by KWANG DONG to unrelated third parties less, on a Licensed
               Product by Licensed Product basis: quantity or cash discount
               allowed or paid by KWANG DONG; credits or allowances given or
               made on account of returns or rejections of previously delivered
               Licensed Products; rebates; insurance premium on sales and sales
               or excise taxes.

Section 1.8.   "NDA shall mean a new drug application as filed with the FDA or
               the foreign equivalent thereof.

Section 1.9.   "Technology" shall mean ADOLOR's confidential know-how,
               processes, instruments, machines, materials, compositions, test
               procedures, manufacturing procedures, techniques, formulations,
               methodologies, data and information.

Section 1.10.  "Territory" shall mean Republic of South Korea, People's Republic
               of North Korea, or any subsequent unification of those countries.

ARTICLE II          LICENSES AND RIGHTS
                    -------------------

Section 2.1.   Licenses and Rights.
               -------------------

(a)  ADOLOR grants to KWANG DONG an exclusive license under Licensed Patents to
     use and sell Licensed Product in the Territory in the Field, without the
     right to sublicense outside of the Territory.

(b)  ADOLOR grants. to KWANG DONG an exclusive license under this Agreement for
     Know-How and Licensed Patent for the manufacture of Licensed Product in the
     Republic of South Korea for sale or use in the Territory. KWANG DONG shall
     not manufacture Licensed Product in any country or territory other than the
     Territory. KWANG DONG shall not directly or indirectly export, sell, or
     offer for sale Licensed Product outside the Territory.

                                      -2-
<PAGE>

(c)  During the term of this Agreement, KWANG DONG shall not work with any party
     other than ADOLOR on the development or use of topical anti-hyperalgesic
     products or any composition which contains ADL 2-1294.

(d)  KWANG DONG may sublicense the right to sell Licensed Product only in the
     Territory, provided however, that Adolor shall have the right to approve
     the sublicense, such approval shall not be unreasonably withheld or
     delayed. Any sublicensee shall comply with all provisions of this
     Agreement.

(e)  Other routes of administration for Licensed Product in dental, ophthalmic,
     mucosal, parenteral, injectable, vaginal and oral forms are presently not
     available. Should ADOLOR develop new routes of administration, ADOLOR shall
     offer KWANG DONG the right of first refusal to acquire a license under
     ADOLOR's intellectual property for the new route of administration in the
     Territory. If ADOLOR develops a new route of administration, ADOLOR will
     notify KWANG DONG in writing and KWANG DONG shall have thirty (30) days
     from the receipt of written notice to provide ADOLOR with written
     notification of KWANG DONG's interest in obtaining the license for the new
     field. ADOLOR and KWANG DONG shall negotiate in good faith for sixty (60)
     days to reach an agreement on the terms of the license. If ADOLOR and KWANG
     DONG are unable to reach an agreement, ADOLOR may enter into an agreement
     with a third party, provided the terms offered by the third party are more
     favorable to ADOLOR than the terms offered by KWANG DONG.

ARTICLE III         INITIATION AND INFORMATION TRANSFER
                    -----------------------------------

Section 3.1.   Technology Transfer
               -------------------

(a)  Following the Effective Date, the parties shall meet at ADOLOR's offices,
     and ADOLOR shall provide detailed data and information related to the
     Formulation including copies of ADOLOR's FDA filings. All data and
     information shall be provided in English.

(b)  ADOLOR shall supply copies of all its patents and patent applications which
     are related to the Licensed Product.

(c)  At KWANG DONG's request, ADOLOR shall make it's scientists and technical
     personnel available at the offices of KWANG DONG not to exceed two times
     each year of this Agreement not to exceed ten (10) man days in total at no
     cost to KWANG DONG. If KWANG DONG requires additional assistance, ADOLOR
     will use reasonable efforts to provide it provided that such request is
     reasonable in ADOLOR's opinion.

ARTICLE IV          PRODUCT DEVELOPMENT
                    -------------------

Section 4.1.   Overview.
               --------

     During the term of this Agreement, KWANG DONG shall use its best efforts to
     obtain regulatory approval and to commercialize the Licensed Product in the
     Field in the Territory. KWANG DONG is solely responsible for the
     expeditious development of the

                                      -3-
<PAGE>

     Licensed Product in the Territory. There will be quarterly meetings
     alternating between ADOLOR's offices and KWANG DONG's offices to exchange
     data. ADOLOR will review KWANG DONG's clinical development program
     including any necessary clinical protocols and agree to recommend
     modifications or improvements; however, KWANG DONG shall be solely
     responsible for the design of its clinical development program.

Section 4.2.   Communication.
               -------------

     From time to time, but at least within 45 days after the end of each
     quarter, KWANG DONG shall provide ADOLOR with a detailed written report of
     KWANG DONG's progress in commercially developing the Licensed Product.
     Such reports shall include, among other information, details of KWANG DONG'
     s Formulations of Licensed Product, all test results and clinical results,
     and documentation of any adverse reactions. All adverse reactions which are
     reportable to the FDA shall be provided to ADOLOR within 24 hours. Prior to
     the approval of Licensed Product by the U.S. FDA, ADOLOR agrees to provide
     quarterly progress reports to KWANG DONG on the progress of its clinical
     development program for Licensed Product

Section 4.3.   Filing Requirements
               -------------------

     KWANG DONG has the responsibility for and shall bear the expense of
     obtaining all approvals of the relevant governmental agencies in the
     Territory including the Republic of Koreas Ministry of Health and Welfare
     ("MOHW") in order to implement the provisions of this Agreement. Following
     approval of an NDA for Licensed Product in United States or another major
     market such as United Kingdom, Germany or Japan, KWANG DONG will use its
     best efforts to file the Korean equivalent of an NDA with MOHW.

ARTICLE V           MANUFACTURE AND SUPPLY
                    ----------------------

Section 5.1.   Formulation Supply
               ------------------

(a)  During the development of the Licensed Product ADOLOR shall supply KWANG
     DONG with reasonable amounts of Formulation within ADOLOR's ability to
     produce at ADOLOR's fully allocated cost, but with no profit; provided,
                                                                   ---------
     however, that KWANG DONG shall use such Formulation solely for obtaining
     -------
     regulatory approval and shall not sell the Formulation.

(b)  ADOLOR agrees to provide three (3) percent of the quantity of bulk
     Formulation sold by KWANG DONG in the Territory in the first year
     immediately following the first commercial sale of Licensed Product at no
     cost to KWANG DONG.

Section 5.2.   ADL2-1294 Supply
               ----------------

     During the term of this Agreement KWANG DONG shall purchase the bulk
     Formulation of ADL2-1294 or Licensed Product from ADOLOR or ADOLOR's
     designee provided that the price, quality and service are competitive. The
     supply of ADL2-1294 shall be the

                                      -4-
<PAGE>

     subject of a separate agreement in accordance with this Section 5.2. In the
     event KWANG DONG can demonstrate that Formulation from ADOLOR or ADOLOR's
     designee is not competitive, then KWANG DONG shall under this Agreement
     have the right to manufacture Licensed Product in the Republic of South
     Korea for use in the Territory. However, the parties agree that ADOLOR or
     ADOLOR's designee will manufacture the Licensed Product or a portion
     thereof, and will negotiate in good faith a separate supply agreement.

Section 5.3.   Non-transfer
               ------------

     KWANG DONG shall not transfer or disclose to any third parties Know How or
     Technology directed to or related to the manufacture or preparation of
     Licensed Product including the Formulation.

ARTICLE VI          SALES
                    -----

Section 6.1.   Sales Efforts.
               -------------

(a)  KWANG DONG agrees to launch the marketing and sales of the Licensed Product
     in the Territory within three (3) months of obtaining government regulatory
     approval for the reimbursement pricing for Licensed Product.

(b)  KWANG DONG shall use its best efforts to market and sell the Licensed
     Product in the Territory.

Section 6.2.   Termination of License.
               ----------------------

     Notwithstanding any other provision of this Agreement, if KWANG DONG has
     not made a commercial sale of a Licensed Product within three (3) years of
     FDA approval, ADOLOR shall have the right to terminate this Agreement if
     the cause of such delay is not directly attributable to ADOLOR'S failure to
     perform its obligations under this Agreement.

ARTICLE VII         PAYMENTS AND ROYALTIES; REPORTS; RECORDS
                    ----------------------------------------

Section 7.1.   Milestones and Payments.
               -----------------------

     As partial consideration for the license granted in this Agreement, certain
     payments shall be made by KWANG DONG upon reaching identified milestones,
     provided, that such payment shall be made after the execution of this
     Agreement:

     (i)    within thirty (30) days following KWANG DONG's receipt of a written
            notice that ADOLOR has successfully completed the Phase II clinical
            trials in a major pharmaceutical market, KWANG DONG shall pay ADOLOR
            U.S.$400,000; provided, however, that such milestone payment shall
                          -----------------
            be reduced by five percent (5%) if Phase II completion occurs after
            July 17th, 1999 and on or before October

                                      -5-
<PAGE>

            16th, 1999; or by 10% if Phase II completion occurs after October
            16th, 1999 and on or before April 15, 2000; or by twenty percent
            (20%) in the event Phase II completion occurs after April 15, 2000.

     (ii)   within thirty (30) days following receipt of a written notice that
            the U.S. FDA or its counterpart in any other major pharmaceutical
            market approved the sale of Licensed Product, KWANG DONG shall pay
            ADOLOR U.S. $400,000; provided, however, that such milestone payment
                                  -----------------
            shall be reduced by ten percent (10%) in the event such NDA approval
            is granted after September 30, 2001 and on or before December 31,
            2001; or by twenty percent (20%) in the event such NDA approval is
            granted after December 31, 2001 and on or before June 30, 2002; or
            by forty percent (40%) in the event such NDA approval is granted
            after June 30, 2002.

     (iii)  Notwithstanding the provision of Section 7.1(i), in the event an NDA
            is approved in any major pharmaceutical market on or before June 30,
            2001 and the milestone payment pursuant to Section 7.1 (i) above was
                 ---
            reduced, then, the amount of any such reduction or reductions shall
            be paid to ADOLOR concurrent with the milestone payment due under
            Section 7.1 (ii).

Section 7.2.   Royalties.
               ---------

(a)  KWANG DONG shall pay to ADOLOR a running royalty, in the Territory, with
     respect to the sale of the Licensed Products whose composition, manufacture
     or use is covered by a Licensed Patent, for a term that shall continue
     until the expiration of the last to expire licensed patent covering ADL 2-
     1294, equal to:

     (i)    ** percent (**) of the annual Net Sales of the

first ** Won except that such royalty rate shall be ** percent (**%) and **
percent (**%) in the first and second consecutive twelve month periods following
the first commercial sales of Licensed product by KWANG DONG respectively under
this Agreement;

     (ii)   ** percent (**%) of the annual Net Sales of greater than ** Won up
            to ** Won; and

     (iii)  ** percent (**%) of the annual Net Sales greater than **
            Won.

(b)  ADOLOR's right to royalties accrues upon the sale of Licensed Products by
     KWANG DONG. Licensed Products shall be deemed sold when invoiced or
     shipped, whichever occurs earlier.

Section 7.3.   Reports.
               -------

     Within forty-five (45) days after the end of each calendar quarter (whether
     or not, a royalty payment is due for that period), KWANG DONG shall provide
     ADOLOR with a written statement with respect to such period specifying the
     gross sales of Licensed Product in the Territory, the calculation of Net
     Sales, the Net Sales of Licensed Product

**=Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to
   the omitted portions.

                                      -6-
<PAGE>

     during the period; and the amount of any royalty due, if any. KWANG DONG.
     shall provide the basis for its calculations of Net Sales.

Section 7.4.   Records.
               -------

(a)  KWANG DONG shall keep complete and accurate records pertaining to the
     formulation, manufacture, use and sale of Licensed Products appropriate to
     determine royalties payable under Section 7.2 of this Agreement.

(b)  At the request and expense of ADOLOR, upon KWANG DONG's prior written
     approval, which shall not be unreasonably withheld or delayed, an
     independent certified accountant selected by ADOLOR shall have access, at
     KWANG DONG's principal place of business in Seoul, South Korea during
     ordinary business hours, to such records maintained by KWANG DONG in
     relation to the sale or sales of Licensed Products or Formulations pursuant
     to this Agreement as may be necessary to:

     (i)    Determine with respect to any of the three (3) preceding years the
            correctness of any report or payment made under this Agreement; or

     (ii)   Obtain information as to the royalty payable in the case of KWANG
            DONG's failure to report or pay pursuant to this Agreement. The
            accountant shall not disclose to ADOLOR or any third parties any
            information relating to the business of KWANG DONG other than
            information relating solely to the accuracy of the reports and
            payments under this Agreement. If the accountant determines that
            KWANG DONG has under-reported the royalties due ADOLOR, then the
            additional royalties due shall within ten (10) days be paid by KWANG
            DONG to ADOLOR along with liquidated damages of one and one-half
            percent (1.5%) per month for the under-reported amount. In the event
            the under-reported amount for any calendar year exceeds five percent
            (5%), then KWANG DONG shall reimburse ADOLOR for the professional
            fees and expenses of the accountant.

Section 7.5.   Payment of Royalty.
               ------------------

(a)  KWANG DONG shall make quarterly royalty payments due under Section 7.2 for
     sales of the Licensed Product. Within forty-five (45) days following the
     end of a fiscal quarter KWANG DONG shall submit the quarterly report due
     under Section 7.3.

(b)  Any royalty due hereunder shall be paid in United States funds collectible
     at par in New York, New York, USA. For the purposes of computing the
     royalty on Net Sales of Licensed Product hereunder, royalty shall first be
     determined in the foreign funds in which sold (herein called "Selling
     Funds") and then converted into its equivalent of the United States funds
     at the selling rate as it appears in the "Currency Rates in New York"
     section of the Asian Wall Street Journal for the last day of each calendar
     month with report due to U.S. in under Section 7.3 with a Letter of Credit
     for the amount of the royalty payment due. The Letter of Credit shall be
     irrevocable, payable in 120 days from the end of the quarter on
     demand/sight to ADOLOR.

                                      -7-
<PAGE>

(c)  Any sum required under the laws of any governmental authority to be
     withheld by KWANG DONG from payment for the account of ADOLOR including
     payments under Section 7.1 and royalties under Section 7.2 shall be
     promptly paid by KWANG DONG for and on behalf of ADOLOR to the appropriate
     tax or other governmental authorities and KWANG DONG. shall furnish ADOLOR
     with copies of the official tax receipts or other appropriate evidence
     issued by the appropriate tax or other government authorities to enable
     ADOLOR to support a claim for tax or other credit or refund in respect of
     any sum so withheld.

ARTICLE VIII        TECHNICAL ASSISTANCE
                    --------------------

Section 8.1.   Overview.
               --------

     ADOLOR shall give KWANG DONG, at KWANG DONG's request, such advice and
     assistance as ADOLOR shall be aware of for the manufacture or use of the
     Licensed Product.

Section 8.2.   Additional Work.
               ---------------

     During the term of this Agreement, ADOLOR shall endeavor from time to time
     inform KWANG DONG of new information which may be useful to KWANG DONG in
     the formulation, use and sale of Licensed Product.

ARTICLE IX          PRODUCT LIABILITY
                    -----------------

Section 9.1.   Product Liability.
               -----------------

(a)  KWANG DONG shall indemnify and hold ADOLOR harmless against all claims,
     losses, expenses and damages awarded by a court of competent jurisdiction
     and reimburse ADOLOR for all reasonable legal fees and costs incurred by
     ADOLOR in defense of such claims, arising from the manufacture, use or sale
     of Licensed Product by KWANG DONG. ADOLOR shall have no liability or
     responsibility for the manufacture, product specifications or end-uses of
     Licensed Product.

(b)  ADOLOR shall give KWANG DONG prompt written notice of any. claim against
     ADOLOR for which ADOLOR may or does seek indemnification under this
     Section, and KWANG DONG shall be solely responsible for the defense and
     financial settlement of such claim.

(c)  ADOLOR shall use its commercial best efforts to cause any supplier of
     Licensed Product to KWANG DONG arranged by ADOLOR to make KWANG DONG the
     beneficiary of any warranty or indemnity provided by such supplier in
     connection with the manufacture of the Licensed Product being so supplied
     (or, in lieu thereof, to pass through without additional liability on the
     part of ADOLOR any benefit of any such warranty or indemnity actually
     received by ADOLOR from such supplier).

                                      -8-
<PAGE>

ARTICLE X           CONFIDENTIALITY
                    ---------------

Section 10.1.  Nondisclosure and Non-use.
               -------------------------

     KWANG DONG and ADOLOR shall each retain in confidence information obtained
     from the other under this Agreement and shall not disclose such information
     to any third parties except as provided for in Section 10.2 of this
     Article. Any confidential information disclosed under any other agreement
     entered into between the two parties shall be deemed to have been disclosed
     under the provisions of this Article X and shall be governed by the terms
     of this Article X.

Section 10.2.  Exceptions.
               ----------

(a)  The obligations of nondisclosure and nonuse of this Article X shall not
     apply to information which:

     (i)    is known to either party as evidence by written records maintained
            by the receiving party, or to the public, prior to its disclosure
            under this Agreement;

     (ii)   is hereafter lawfully disclosed to the receiving party by a third
            party not under an obligation of confidence to the other party; or

     (iii)  subsequently becomes known to the public by some means other than a
            breach of this Agreement.

(b)  ADOLOR and KWANG DONG shall each retain in confidence information obtained
     from the other under this Agreement and shall not disclose such information
     to any third party except:

     (i)    consultants who are obligated to maintain in confidence pursuant to
            written agreements which incorporate by reference the terms of this
            Article;

     (ii)   as necessary to obtain approval from a governmental agency in order
            to market the product;

     (iii)  as reasonably may be required in a patent application covering
            subject matter which is encompassed within this Agreement; or

     (iv)   as otherwise may be required by law, regulation or judicial order,
            and shall not use such information for any purposes other than those
            contemplated by this Agreement. Each party shall take all reasonable
            precautions to safeguard the confidentiality of the information.

                                      -9-
<PAGE>

Section 10.3.  Purpose of Article.
               ------------------

     Each party acknowledges that the restrictions contained in this Article X
     are necessary and reasonable to protect the legitimate interests of the
     other party and. a violation of this Article may result in irreparable harm
     to the injured party.

Section 10.4.  Term.
               ----

     The provisions of this Article X shall survive the expiration or
     termination of this Agreement and continue for twelve (12) years
     thereafter.

ARTICLE XI          INVENTIONS AND PATENTS
                    ----------------------

Section 11.1.  Results and Data.
               ----------------

     The data and test results of research and development conducted as a result
     of this Agreement are confidential, proprietary and of great value to the
     parties. The data and test results are subject to the terms of Article X of
     this Agreement which are not inconsistent with this Section 11.1. KWANG
     DONG shall not use or disclose the data or test results for any purpose
     other than in accordance with the terms of this Agreement. The data and
     test results shall be deemed to embody Technology. The data and test
     results shall be owned solely by ADOLOR, and ADOLOR shall be free to use
     the data and test results for any purpose, including but not limited to
     disclosure to a third party.

Section 11.2.  Ownership and Patent Applications.
               ---------------------------------

(a)  All inventions, and resulting patent applications and patents, directed to
     or relating to ADL-2- 1294, its composition, formulation, manufacture or
     use, shall be owned solely by ADOLOR.

(b)  All other inventions, other than those of Section 11.2(a), shall belong to
     the party making the invention. All resulting patent applications and
     patents shall belong to the party owning the claimed inventions. For
     jointly made other inventions, ADOLOR and KWANG DONG shall have joint
     rights to such intellectual property and any resulting patents shall be
     jointly owned. KWANG DONG's improvements shall be cross-licensed to ADOLOR.
     Any right for one party to sublicense shall require the prior written
     approval of the other party.

(c)  Neither ADOLOR nor KWANG DONG shall have any right with respect to the
     others Technology, including Know-How and patents, which are not otherwise
     specifically provided for in this Agreement.

(d)  The parties shall agree on a plan to cause Licensed Patent to be marked on
     some conspicuous part of a durable label firmly attached to the Licensed
     Product or to the package for the Licensed Product made or sold under this
     Agreement, in a manner which is easily seen and read and not easily
     defaceable, either:

                                      -10-
<PAGE>

     (i)    if a patent shall have been granted, the patent number applicable to
            such Licensed Patent; or

     (ii)   if a patent shall not have been granted, words indicating that
            letters patent have been applied for, if applicable.

Section 11. 3. Infringement of Third Party's Patent.
               ------------------------------------

(a)  Each party shall notify the other party promptly if, to its knowledge, a
     third party:

     (i)    shall have obtained a patent which discloses or claims the same as a
            Licensed Patent in any country; or

     (ii)   is manufacturing a product based on either a Licensed Patent or the
            same as claimed by a Licensed Patent.

(b)  ADOLOR and KWANG DONG shall notify each, other promptly of any claim of, or
     action for, infringement of any patents belonging to third parties which
     shall have been threatened, or shall have been brought against either party
     by reason of the manufacture, use or sale of the Licensed Product.

(c)  In the event that an action for infringement with regard to the Licensed
     Product shall have been brought, KWANG DONG shall defend such actions at
     its own expense in the Territory. Any action which names ADOLOR shall be
     subject to the indemnification provisions of Section 9 (Product Liability).

(d)  Notwithstanding anything to the contrary in this Agreement, KWANG DONG
     shall not interpose a Licensed Patent as a counterclaim in any legal
     proceeding with a third party.

(e)  ADOLOR shall consult and cooperate with KWANG DONG and provide such other
     nonmonetary assistance as may reasonably be requested.

Section 11.4.  Third-Party Infringement.
               ------------------------

(a)  If either ADOLOR or KWANG DONG learns of an infringement or threatened
     infringement of a Licensed Patent, such party shall notify the other party
     promptly.

(b)  The parties shall promptly meet to decide on the course of action to take.
     ADOLOR may, at its own expense, take steps to prevent or terminate such
     infringement, and KWANG DONG may join in such steps at its own expense. If
     ADOLOR chooses to bring an action at its own expense, KWANG DONG may join
     in such action at its own expense.

(c)  ADOLOR shall retain for itself all recovery from any action commenced to
     prevent or terminate the infringement, unless KWANG DONG shall have joined
     in the action at its own expense as set forth below. KWANG DONG agrees to
     cooperate with ADOLOR and provide such nonmonetary assistance as ADOLOR may
     reasonably request in connection with such action. KWANG DONG may join
     ADOLOR in any such action to

                                      -11-
<PAGE>

     prevent or terminate the infringement in which case any recoveries shall be
     divided between ADOLOR and KWANG DONG after deduction of litigation
     expenses in proportion to the financial contributions each party makes to
     the total cost of the action.

(d)  Should ADOLOR not pursue action to prevent or terminate an alleged
     infringement per Section 11.4(b), KWANG DONG may then, at its sole expense,
     pursue action to prevent or terminate the infringement, and retain any
     recoveries which it shall obtain for such infringement. ADOLOR agrees to
     cooperate with KWANG DONG and provide such nonmonetary assistance as KWANG
     DONG may reasonably request in connection with any such action.

Section 11.5.  Patent Costs.
               ------------

     KWANG DONG acknowledges that the Licensed Patents are the property of
     ADOLOR and KWANG DONG shall not challenge or contest ADOLOR's intellectual
     property rights including that of Licensed Patents. ADOLOR shall control
     the patent prosecution procedure and be responsible for the costs incurred
     in doing so.

Section 11.6.  ADOLOR's Work.
               -------------

     The results of all work undertaken by ADOLOR in the development and
     commercialization of the Licensed Product shall be sole property of ADOLOR
     and KWANG DONG shall have no right, title or interest thereto except as
     provided under this Agreement.

Section 11.7.  Accuracy and Ownership of Information Disclosed.
               -----------------------------------------------

     Information disclosed by each party to the other shall be accurate to the
     best of the disclosing party's knowledge, but neither party expressly or
     implicitly warrants as to the accuracy of such information. Neither party
     represents that the use of the information disclosed to the other party
     pursuant to this Agreement, or the manufacture, sale, or use of Licensed
     Products does not infringe upon the rights of a third party. All
     information furnished by a party pursuant to this Agreement shall remain
     the sole and exclusive property of the disclosing party. Either party may
     refuse to disclose and defer disclosure of information to the other party
     to the extent such information is either unnecessary for the purposes of
     this Agreement or not subject to disclosure under this Agreement.-

ARTICLE XII - EXPIRATION AND TERMINATION
              --------------------------

Section 12.1.  Expiration of Patent.
               --------------------

(a)  Unless terminated earlier under other provisions of this Agreement, this
     Agreement will expire upon the expiration of the last obligation to pay
     royalties under Section 7.2.

(b)  In the event a product containing the same pharmaceutically active
     substance and formulation for the treatment of the same therapeutic
     indication as Licensed Product is

                                      -12-
<PAGE>

     approved for sale and is actively sold in commercial quantities in the
     Territory, ADOLOR and KWANG DONG shall meet and discuss the impact of such
     "approved me too product" on the royalty due to ADOLOR.

Section 12.2.  Termination without Cause.
               -------------------------

     KWANG DONG shall be free to terminate this AGREEMENT at any time prior to
     commercial launch of Licensed Product upon ninety (90) days prior written
     notice, and at any time after commercial launch of Licensed Product, upon
     one (1) year's prior written notice. Any monies owed to ADOLOR prior to the
     termination shall be promptly paid to ADOLOR upon the effective date of
     termination.

Section 12.3.  Material Defaults.
               -----------------

(a)  Either party may terminate this Agreement upon sixty (60) days' prior
     written notice in the event of the other party's breach of any other
     material provision of this Agreement, if such default or breach is not
     remedied within thirty (30) days from the date of such notice.

(b)  A material default includes, but is not limited to:

     (i)    sale or export by KWANG DONG of Formulation or Licensed Product
            outside the Territory;

     (ii)   sale by KWANG DONG of Formulation or Licensed Product to a third
            party who sells or exports the formulation or Licensed Product
            outside the Territory;

     (iii)  failure to make any payments or reports due under this Agreement;

     (iv)   sublicensing by KWANG DONG of the license under this Agreement
            except as provided under Section 2.1 (d); or

     (v)    failure by KWANG DONG to use its best efforts to pursue regulatory
            approval of Licensed Product; or

     (vi)   failure by KWANG DONG to use its best effort to maximize sales of
            Licensed Product in the Territory following regulatory approval.

(c)  Any failure to terminate shall not be construed as a waiver by the
     aggrieved party of its rights to terminate for future defaults or breaches.

Section 12.4.  Bankruptcy.
               ----------

     If, during the term of this Agreement, KWANG DONG makes an assignment for
     the benefit of creditors, or shall go into liquidation, or a receiver or
     trustee shall be appointed for its property, or if proceedings for
     voluntary bankruptcy are instituted or KWANG DONG is declared bankrupt or
     insolvent, by a court of competent jurisdiction, ADOLOR

                                      -13-
<PAGE>

     may terminate this Agreement immediately upon delivery of written notice to
     KWANG DONG.

Section 12.5.  Surviving Rights.
               ----------------

     The provisions of Sections 7.5, 12.6, 13.2 and Articles IX, X, and XI of
     this Agreement shall survive the expiration or termination of this
     Agreement.

Section 12.6.  Effects of Termination.
               ----------------------

(a)  Upon termination of this Agreement, each party shall, upon request, return
     all books, records, documents and data which was received from the other
     party pursuant to this Agreement, provided that this provision shall not be
     applied in case this Agreement is terminated by either party pursuant to
     Section 12.3 and 12.4.

(b)  Termination of this Agreement by either party shall not prejudice the right
     of ADOLOR to recover any royalty or other payments due at the time of
     termination and shall not prejudice any cause of claim of action of either
     party accruing under this Agreement.

(c)  Upon termination of this Agreement ADOLOR shall be free to enter into
     agreements with third parties for the use of ADOLOR's technical information
     to develop, make, use, or sell products containing ADL 2-1294 in the
     Territory subject to the terms of Article X of this Agreement.

ARTICLE XIII        MISCELLANEOUS PROVISIONS
                    ------------------------

Section 13.1.  Entire Understanding.
               --------------------

     This Agreement sets forth the entire understanding between ADOLOR and KWANG
     DONG pertaining to its subject matter and supersedes and replaces all prior
     oral or written agreements between ADOLOR and KWANG DONG pertaining to such
     subject matter, including but not limited to, the Letter of Intent of May
     22, 1997.

Section 13.2.  Amendments.
               ----------

     This Agreement may not be amended, supplemented or otherwise modified
     except by an instrument in writing signed by both parties.

Section 13.3.  Assignment.
               ----------

     KWANG DONG shall not assign this Agreement. ADOLOR shall be free to assign
     this Agreement following prior written notice to KWANG DONG in connection
     with the sale or transfer of ADOLOR's business, or the sale or merger of
     ADOLOR and this Agreement shall survive in the event of such change.

                                      -14-
<PAGE>

Section 13.4.  Waiver.
               ------

     No provision of this Agreement shall be waived by any act, omission, or
     knowledge of a party or its agents or employees, except by an instrument in
     writing expressly waiving such provision and signed by the waiving party.

Section 13.5.  Governing Law.
               -------------

     This Agreement shall be governed by and interpreted under the laws of the
     State of Pennsylvania, without regard to conflicts of law. Venue shall be
     in Philadelphia, Pennsylvania.

Section 13.6.  Restriction of Distribution of this Agreement.
               ---------------------------------------------

     This Agreement shall not be distributed to persons other than those
     personnel of ADOLOR and KWANG DONG and ADOLOR's affiliates and sublicensees
     who have a need to know its contents and those whose knowledge of the
     contents will facilitate the performance of the obligations of the parties
     under this Agreement, and others as may be required by law, regulation or
     judicial order.

Section 13.7.  Consents not Unreasonably Withheld or Delayed.
               ---------------------------------------------

     Whenever provision is made in this Agreement for either party to secure the
     consent or approval of the other, such consent or approval shall not be
     unreasonably withheld or delayed.

Section 13.8.  Construction.
               ------------

     The captions appearing in this Agreement are for reference purposes only
     and shall not be considered for the purposes of interpreting or construing
     this Agreement. The plural shall be substituted for singular numbers in any
     place in which the context may require such substitution.

Section 13.9.  Invalidity of Particular Provisions.
               -----------------------------------

     If any provision of this Agreement is invalid or unenforceable by reason of
     any rule or law, administrative order or judicial decision, all other
     provisions of this Agreement shall remain in full force and effect. The
     parties shall reform such provisions to most closely reach the desired end
     of the provision while overcoming the invalidity or unenforceability.

Section 13.10. Currency.
               --------

     All amounts preceded by a dollar sign shall mean United States dollars
     unless otherwise stated. All amounts in Won shall be in Republic of South
     Korea currency.

                                      -15-
<PAGE>

Section 13.11. Publicity.
               ---------

     Subject to Article X, either party shall be free to publicize the existence
     and purpose of this Agreement; However, each party shall provide a copy of
     proposed press releases related to matters pursuant to this Agreement to
     the other party for comment prior to the issuance of such press release.

Section 13.12. Notices.
               -------

     Any notice or report required or permitted hereunder shall be given in
     writing by personal delivery or by registered or certified mail, return
     receipt requested, postage prepaid, and, if sent by mail, shall be
     effective upon delivery to the following addresses:

     ADOLOR CORPORATION

     371 Phoenixville Pike
     Malvern PA 19355
     Attention:  President

     KWANG DONG PHARMACEUTICAL COMPANY, LTD.

     212-13, Kuro-Dong
     Kuro-ku
     Seoul, South Korea
     Attention: President

     or such address as a party may designate by prior written notice to the
     other party.

Section 13.13. Wire Transfer

     All payments to ADOLOR shall be made by wire transfer in immediately good
     and transferable funds. ADOLOR shall provide KWANG DONG with standing wire
     transfer instructions.

Section 13.14. Language

     This Agreement is executed in two original English counterparts, each of
     which shall be deemed an original. The English text of the Agreement shall
     prevail over any translation thereof.

                                      -16-
<PAGE>

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in
duplicate by their duly authorized representative.

ATTEST:                         ADOLOR CORPORATION

Name: /s/ Peter J. Schied       By: /s/ John J. Farrar
     ----------------------        ---------------------------------------------

                                Title: President and Chief Executive Officer
                                      ------------------------------------------

                                Date: November 5, 1997
                                     -------------------------------------------

ATTEST:                         KWANG DONG PHARMACEUTICAL
                                    COMPANY, LTD.

Name: /s/ illegible             By: /s/ Soo Boo Choi
     ----------------------        ---------------------------------------------

                                Title:

                                Date: November 5
                                     -------------------------------------------

                                      -17-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]